September 30th 2024
The event will focus on innovating with cutting-edge technology, featuring the likes of pharmaceutical technology companies revolutionizing the industry.
FDA approves first once-daily eyedrop for inflammation and pain after cataract surgery
November 16th 2010Bromfenac ophthalmic solution (Bromday, ISTA Pharmaceuticals) 0.09% has been granted FDA approval as a once-daily prescription eyedrop for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction.
FDA OKs duloxetine hydrochloride to treat chronic musculoskeletal pain
November 16th 2010In patients with chronic knee pain due to osteoarthritis, 60 mg to 120 mg of duloxetine hydrochloride, a serotonin-norepinephrine reuptake inhibitor (SNRI), administered daily, was found to provide both significant pain control and improve physical functioning.
FDA approves onabotulinumtoxinA to prevent chronic migraine
November 16th 2010FDA has approved onabotulinumtoxinA (Botox, Allergan Inc.) injection to prevent headaches in adult patients with chronic migraine. To prevent chronic migraine, onabotulinumtoxinA is injected about every 12 weeks in multiple sites around the head and neck to try to dull future headache symptoms.
First IV formulation for acetaminophen approved
November 16th 2010FDA has approved acetaminophen injection (Ofirmev, Cadence Pharmaceuticals), the first intravenous formulation of acetaminophen for the management of mild-to-moderate pain, moderate-to severe-pain with adjunctive opioid analgesics, and the reduction of fever.
FDA approves trastuzumab to treat HER2-overexpressing metastatic gastric or gastroesophageal cancer
November 16th 2010FDA approved trastuzumab (Herceptin, Genentech) for use in combination with cisplatin and capecitabine or 5-fluorouracil to treat patients with human epidermal growth factor receptor 2-overexpressing metastatic gastric or gastroesophageal junction cancer who have not received prior treatment for metastatic disease.
Consensus statement lowers BP goals in blacks to manage hypertension
November 16th 2010An updated consensus statement on the management of hypertension among African Americans places significant emphasis on a comprehensive assessment and appropriate risk stratification of individual patients with hypertension, stated a report published online October 4 in Hypertension, HealthDay News reported.
Buprenorphine implants reduce opioid use of opioid-dependent patients
November 16th 2010In a new randomized, placebo-controlled clinical trial published in the October 13, 2010 Journal of the American Medical Association, trial investigators demonstrated that the use of buprenorphine implants (Probuphine, Titan Pharmaceuticals) could reduce opioid use over a 24-week study period.
DECISIONS survey study: Americans often make medication decisions without being well-informed
November 16th 2010According to the findings of the DECISIONS survey study published in a September/October supplement of Medical Decision Making, Americans frequently find themselves faced with high blood pressure, high cholesterol, and depression medication decisions that they are ill prepared to make.
Studies show impact of doctor-pharmacist collaboration
November 16th 2010According to the findings of the DECISIONS survey study published in a September/October supplement of Medical Decision Making, Americans frequently find themselves faced with high blood pressure, high cholesterol, and depression medication decisions that they are ill prepared to make.